Category - Developments

Developments

Aurinia posts positive Phase 2b voclosporin results

Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) voclosporin achieved its primary endpoint of complete remission (CR) at 24 weeks in a Phase 2b trial. In addition, when both doses of voclosporin were added to the current...

September 30, 2016

Developments

Galectin completes enrollment in Phase 2b trial ahead of schedule

Galectin Therapeutics (NASDAQ:GALT) has completed enrollment one month early in its Phase 2b trial (NASH-CX) with 162 subjects with nonalcoholic steatohepatitis (NASH). The Phase 2b study is testing the company’s GR-MD...

September 28, 2016

Developments

Opioid addiction patient gives high marks to Titan’s Probuphine

USA Today has carried a profile of Sarah Wilson, wife and mother of four, who became addicted to opioid pain medications after she suffered severe injuries from being hit by an intoxicated driver about eight-years-ago...

September 27, 2016

Developments

Dresner Partners opens office in Florida

Dresner Partners has opened a new office in Fort Lauderdale, FL to be headed by Mitchell Stern, managing director and head of Dresner Partners’ healthcare practice. Mr. Stern will also continue to spend a portion of...

September 27, 2016

Developments

FDA grants orphan drug status to Soricimed’s SOR-C13

The FDA has granted orphan drug designation to closely-held Soricimed Biopharma’s peptide, SOR-C13, for the treatment of pancreatic cancer, following a similar designation for ovarian cancer In a statement, Paul Gunn...

September 27, 2016

Developments

Mateon collaborates with US Oncology Research

US Oncology Research will participate in Mateon Therapeutics’ (NASDAQ:MATN) FOCUS clinical trial in platinum-resistant ovarian cancer. In a statement, Dr. William Schwieterman, president and CEO of Mateon, said US...

September 26, 2016

Developments

Global Kinetics gets FDA okay for Parkinson’s KinetiGraph

Australia-based Global Kinetics has received 510(k) marketing clearance from the FDA for its next generation, wrist-worn Parkinson’s KinetiGraph (PKG) System. The new PKG technology enables a shift to “anywhere...

September 22, 2016

Developments

Profound Medical treats first patient in TACT pivotal trial

The first patient has been treated in Profound Medical’s (TSX-V:PRN) TACT pivotal trial at Vanderbilt University Medical Center in Nashville, TN. TACT is a prospective, single-arm pivotal clinical study of 110 patients...

September 22, 2016

Developments

Appeals court upholds LifeNet’s patent victory

The U.S. Court of Appeals for the Federal Circuit upheld a Virginia federal jury award to LifeNet Health of $34.7-million in damages for LifeCell’s infringement of a LifeNet patent related to improving the...

September 19, 2016

Developments Markets

TearLab to request NASDAQ hearing over listing

TearLab (NASDAQ:TEAR; TSX:TLB) has received a letter from the Nasdaq listing qualifications staff, indicating that the company failed to regain compliance with the $1 minimum bid price requirement for continued listing...

September 19, 2016

Category - Developments

Subscribe